If there is one thing decades of studies with tens of thousands of heart disease patients have revealed, it is that lowering cholesterol can reduce the risk of heart attacks and deaths. Now, with new drugs on the market that can plunge cholesterol levels lower than ever thought possible, researchers are eagerly waiting for an answer to the next question: Is there a limit to the benefits in high-risk patients? After a certain point, do benefits level off or even reverse?
A new study suggests there is no leveling off. But that good news comes in the context of unexpected problems with the new drugs, known as PCSK9 inhibitors.
More at New York Times